GRTS - Gritstone Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Gritstone Oncology, Inc.

5858 Horton Street
Suite 210
Emeryville, CA 94608
United States

Full Time Employees164

Key Executives

NameTitlePayExercisedYear Born
Dr. Andrew R. AllenCo-Founder, Pres, CEO & Director730.85kN/A1967
Mr. Jean-Marc Bellemin M.B.A.Exec. VP of Fin. & CFO540.66kN/A1972
Dr. Roman YelenskyExec. VP & CTO472.78kN/A1979
Dr. Karin JoossExec. VP of Research & Chief Scientific OfficerN/AN/A1965
Mr. Mike ForchtSr. VP of HRN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Corporate Governance

Gritstone Oncology, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.